These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 36949429)
1. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer. Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429 [TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma. Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979 [TBL] [Abstract][Full Text] [Related]
3. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
4. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer. Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405 [TBL] [Abstract][Full Text] [Related]
5. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
6. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis. Yin C; Gao M; Wang Q; Li H Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319 [TBL] [Abstract][Full Text] [Related]
7. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma. Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546 [TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774 [TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients' survival. Liu F; Wu X J Gastrointest Oncol; 2023 Apr; 14(2):650-662. PubMed ID: 37201038 [TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis. Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343 [TBL] [Abstract][Full Text] [Related]
11. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer. Liu L; Wang Q; Zhou JY; Zhang B J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030 [TBL] [Abstract][Full Text] [Related]
12. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia. Zhu Y; He J; Li Z; Yang W BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692 [TBL] [Abstract][Full Text] [Related]
14. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Pan Y; Zhang Q; Zhang H; Kong F Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225 [TBL] [Abstract][Full Text] [Related]
16. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z Front Immunol; 2022; 13():951455. PubMed ID: 36189298 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
18. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma. Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086 [TBL] [Abstract][Full Text] [Related]
19. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Liu Y; Jiang J Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878 [TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis-related lncRNA for predicting prognosis and immunotherapeutic response in cervical cancer. Kong X; Xiong Y; Xue M; He J; Lu Q; Chen M; Li L Sci Rep; 2023 Jul; 13(1):10697. PubMed ID: 37400520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]